CY1110661T1 - Αντισωματα συνδεομενα με τον ανθρωπινο μαγικο μυλο (mr), πολυπεπτιδια και χρησεις τους για την αναστολη της αγγειογενεσεως - Google Patents

Αντισωματα συνδεομενα με τον ανθρωπινο μαγικο μυλο (mr), πολυπεπτιδια και χρησεις τους για την αναστολη της αγγειογενεσεως

Info

Publication number
CY1110661T1
CY1110661T1 CY20101100595T CY101100595T CY1110661T1 CY 1110661 T1 CY1110661 T1 CY 1110661T1 CY 20101100595 T CY20101100595 T CY 20101100595T CY 101100595 T CY101100595 T CY 101100595T CY 1110661 T1 CY1110661 T1 CY 1110661T1
Authority
CY
Cyprus
Prior art keywords
individual
polypalpteses
vascular
reduce
administering
Prior art date
Application number
CY20101100595T
Other languages
English (en)
Inventor
Roy Bicknell
Steven Suchting
Lorna Mary Dyet Stewart
Original Assignee
Cancer Research Technology Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32328072&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1110661(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0227080A external-priority patent/GB0227080D0/en
Priority claimed from GB0321401A external-priority patent/GB0321401D0/en
Application filed by Cancer Research Technology Limited filed Critical Cancer Research Technology Limited
Publication of CY1110661T1 publication Critical patent/CY1110661T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Μέθοδος αναστολής της αγγειογενέσεως σε ένα άτομο το οποίο την έχει ανάγκη περιλαμβάνουσα τη χορήγηση ενός αντισώματος το οποίο συνδέεται επιλεκτικά με την εξωκυτταρική περιοχή του ανθρώπινου μαγικού μύλου (MR) στο άτομο. Αντίσωμα το οποίο έχει τις αλληλουχίες αμινοξέων i) έως iii), τις αλληλουχίες αμινοξέων iv) έως vi) ή τις αλληλουχίες αμινοξέων i) έως vi): i) S A S S S V S Υ Μ Y ii) L Τ S Ν L A S iii) Q Q W S S Ν Ρ L Τ iv) D Y N L N v)V I N P N Y G T T S Y N Q K F K G vi) G R D Y F G Y. Μέθοδος αναστολής της αγγειογενέσεως σε ένα άτομο το οποίο την έχει ανάγκη περιλαμβάνουσα τη χορήγηση του εξωκυτταρικού τομέα (κατάλοιπα 1-467) του MR ή ενός θραύσματος του το οποίο αναστέλλει την αγγειογένεση στο άτομο. Μέθοδος αναστολής της μεταναστεύσεως και/ή του πολλαπλασιασμού των ενδοθηλιακών κυττάρων περιλαμβάνουσα τη χορήγηση του εξωκυτταρικού τομέα του MR ή ενός θραύσματος του το οποίο αναστέλλει τη μετανάστευση και/ή τον πολλαπλασιασμό των ενδοθηλιακών κυττάρων.
CY20101100595T 2002-11-20 2010-06-29 Αντισωματα συνδεομενα με τον ανθρωπινο μαγικο μυλο (mr), πολυπεπτιδια και χρησεις τους για την αναστολη της αγγειογενεσεως CY1110661T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0227080A GB0227080D0 (en) 2002-11-20 2002-11-20 Antibodies and uses thereof
GB0321401A GB0321401D0 (en) 2003-09-12 2003-09-12 Antibodies,polypeptides and uses thereof
EP03778499A EP1565491B1 (en) 2002-11-20 2003-11-20 Antibodies binding to human magic roundabout (mr), polypeptides and uses thereof for inhibition of angiogenesis

Publications (1)

Publication Number Publication Date
CY1110661T1 true CY1110661T1 (el) 2015-06-10

Family

ID=32328072

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100595T CY1110661T1 (el) 2002-11-20 2010-06-29 Αντισωματα συνδεομενα με τον ανθρωπινο μαγικο μυλο (mr), πολυπεπτιδια και χρησεις τους για την αναστολη της αγγειογενεσεως

Country Status (15)

Country Link
US (4) US20060099143A1 (el)
EP (1) EP1565491B1 (el)
JP (2) JP4869603B2 (el)
AT (1) ATE462727T1 (el)
AU (1) AU2003285500B8 (el)
CA (1) CA2506724C (el)
CY (1) CY1110661T1 (el)
DE (1) DE60331945D1 (el)
DK (1) DK1565491T3 (el)
HK (1) HK1080869A1 (el)
IL (2) IL168646A (el)
MX (1) MXPA05005470A (el)
PT (1) PT1565491E (el)
SI (1) SI1565491T1 (el)
WO (1) WO2004046191A2 (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036771A2 (en) * 2000-11-06 2002-05-10 Cancer Research Technology Limited Imaging, diagnosis and treatment of disease
US6926081B2 (en) * 2002-02-25 2005-08-09 Halliburton Energy Services, Inc. Methods of discovering and correcting subterranean formation integrity problems during drilling
EP1572169B1 (en) * 2002-03-08 2013-07-17 Shanghai Institutes for Biological Sciences, CAS Detection and modulation of slit and roundabount (robo) mediated angiogenesis and uses thereof
EP1565491B1 (en) * 2002-11-20 2010-03-31 Cancer Research Technology Limited Antibodies binding to human magic roundabout (mr), polypeptides and uses thereof for inhibition of angiogenesis
WO2006089209A2 (en) * 2005-02-17 2006-08-24 The Board Of Trustees Of The Leland Stanford Junior University Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby
US7994130B2 (en) * 2006-12-11 2011-08-09 University Of Utah Research Foundation Compositions and methods for treating ocular pathologic angiogenesis and vascular permeability
MX2009008430A (es) 2007-02-09 2009-10-28 Genentech Inc Anticuerpos anti-robo4 y sus usos.
EP2313435A4 (en) * 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS
PL3023438T3 (pl) 2009-09-03 2020-07-27 Merck Sharp & Dohme Corp. Przeciwciała anty-gitr
WO2011027132A1 (en) 2009-09-03 2011-03-10 Cancer Research Technology Limited Clec14a inhibitors
EP2511365A4 (en) * 2009-10-23 2013-07-03 Rnl Bio Co Ltd METHOD FOR INDUCING MIGRATION OF ADULT STEM CELLS DERIVED FROM ADIPOSE TISSUE
SE535982C2 (sv) * 2009-12-15 2013-03-19 Theravac Pharmaceuticals Ab Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi
JP2013529076A (ja) 2010-05-11 2013-07-18 アベオ ファーマシューティカルズ， インコーポレイテッド 抗ｆｇｆｒ２抗体
GB201115529D0 (en) 2011-09-08 2011-10-26 Imp Innovations Ltd Antibodies, uses and methods
PL2841457T3 (pl) * 2012-04-27 2019-09-30 Daiichi Sankyo Company, Limited Przeciwciało anty-ROBO4
GB201501004D0 (en) 2015-01-21 2015-03-04 Cancer Rec Tech Ltd Inhibitors
WO2022221314A1 (en) * 2021-04-16 2022-10-20 BioLegend, Inc. Compositions and methods involving severe acute respiratory syndrome coronavirus 2 receptor binding domain

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6069007A (en) * 1989-06-21 2000-05-30 City Of Hope Ribozyme cleavage of HIV RNA
US5955291A (en) 1992-01-09 1999-09-21 Alitalo; Kari Antibodies recognizing tie receptor tyrosine kinase and uses thereof
EP0682113A3 (en) 1994-05-12 1996-12-18 Ono Pharmaceutical Co A polypeptide produced in an endothelial cell line and DNA encoding it.
US20040002591A1 (en) * 1997-09-05 2004-01-01 Human Genome Sciences, Inc. 50 human secreted proteins
CA2298852A1 (en) 1997-07-30 1999-02-11 Human Genome Sciences, Inc. 83 human secreted proteins
EP1019091A4 (en) 1997-09-05 2005-05-11 Human Genome Sciences Inc 50 SECRETED PROTEINS OF HUMAN ORIGIN
US6225118B1 (en) * 1997-10-01 2001-05-01 Biocure Limited Multicellular in vitro assay of angiogenesis
PT1490386E (pt) 1998-03-10 2008-11-24 Genentech Inc Novos polipéptidos e ácidos nucleicos que os codificam
EP1068312A2 (en) 1998-04-09 2001-01-17 Genset 5' ests and encoded human proteins
AU2883600A (en) 1999-03-08 2000-09-28 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1074617A3 (en) 1999-07-29 2004-04-21 Research Association for Biotechnology Primers for synthesising full-length cDNA and their use
JP2004515203A (ja) * 1999-08-12 2004-05-27 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒト腫瘍壊死因子レセプターｔｒ１６
WO2001023523A2 (en) 1999-09-30 2001-04-05 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
WO2002036771A2 (en) 2000-11-06 2002-05-10 Cancer Research Technology Limited Imaging, diagnosis and treatment of disease
EP1572169B1 (en) * 2002-03-08 2013-07-17 Shanghai Institutes for Biological Sciences, CAS Detection and modulation of slit and roundabount (robo) mediated angiogenesis and uses thereof
US20060160729A1 (en) 2002-06-27 2006-07-20 Li Dean Y Methods and compositions for manipulating the guided navigation of endothelial tubes during angiogenesis
EP1565491B1 (en) 2002-11-20 2010-03-31 Cancer Research Technology Limited Antibodies binding to human magic roundabout (mr), polypeptides and uses thereof for inhibition of angiogenesis

Also Published As

Publication number Publication date
US20060263369A1 (en) 2006-11-23
SI1565491T1 (sl) 2010-08-31
ATE462727T1 (de) 2010-04-15
AU2003285500A1 (en) 2004-06-15
PT1565491E (pt) 2010-07-06
DE60331945D1 (de) 2010-05-12
WO2004046191A3 (en) 2004-07-29
WO2004046191A2 (en) 2004-06-03
IL168646A (en) 2010-12-30
DK1565491T3 (da) 2010-07-19
JP2012050442A (ja) 2012-03-15
JP5336566B2 (ja) 2013-11-06
AU2003285500B8 (en) 2011-02-03
AU2003285500B2 (en) 2010-07-01
US8394381B2 (en) 2013-03-12
MXPA05005470A (es) 2005-09-08
CA2506724A1 (en) 2004-06-03
HK1080869A1 (en) 2006-05-04
EP1565491A2 (en) 2005-08-24
US20080166295A1 (en) 2008-07-10
JP4869603B2 (ja) 2012-02-08
JP2006524485A (ja) 2006-11-02
US20080019963A1 (en) 2008-01-24
CA2506724C (en) 2013-03-12
US20060099143A1 (en) 2006-05-11
IL204453A (en) 2014-02-27
EP1565491B1 (en) 2010-03-31

Similar Documents

Publication Publication Date Title
CY1110661T1 (el) Αντισωματα συνδεομενα με τον ανθρωπινο μαγικο μυλο (mr), πολυπεπτιδια και χρησεις τους για την αναστολη της αγγειογενεσεως
CY1119243T1 (el) Φαρμακοτεχνικες μορφες ανταγωνιστη του vegf
NZ605429A (en) Therapeutic human anti-il-1r1 monoclonal antibody
TR199801390T2 (xx) Tromboz tedavisinde kullan�lacak p�ht�la�may� �nleyici maddeler
DK1266025T3 (da) Protein-scaffolds for antistof-mimetika og andre bindingsproteiner
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
ATE196314T1 (de) Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit
ATE432986T1 (de) Menschlicher rezeptor für tumor necrosis factor
SE9901379D0 (sv) Receptor structures
ATE234111T1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
DE69534180D1 (de) Promotor der tie rezeptor protein kinase
ATE407698T1 (de) Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung
DE60125563D1 (de) Verfahren zur verwendung eines humanen il-17 verwandten polypeptids zur behandlung von krankheiten
ATE193022T1 (de) Heparin-und sulfatid-bindende peptide vom typ 1 der wiederkehrenden sequenzen vom menschlichen thrombospondin
ATE466020T1 (de) Neue isoform des gefässendothelzell wachstumshemmers (vegi)
NO20026286D0 (no) Nye peptider
DK1397380T3 (da) Multipelt antigent peptid, der udviser flere kopier af en epitop af et plaquedannende polypeptid, og fremgangmåder til anvendelse deraf
DE69115917D1 (de) Humane gammainterferonantagonisten
JP2004511492A5 (el)
DE69840326D1 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
RS52448B (en) ANTITUMOR PHARMACEUTICAL COMPOSITION CONTAINING SERALIZIN POLYPEPTIDE FRAGMENTS
IL177698A0 (en) Fusion proeins comprising modified allergens of the ns-ltps family, use thereof and pharmaceutical compositions comprising the same
Heal et al. A search within the IL-1 type I receptor reveals a peptide with hydropathic complementarity to the IL-1β trigger loop which binds to IL-1 and inhibits in vitro responses
NO961423D0 (no) Oligopeptider avledet fra C-reaktive proteinfragmenter
ATE414279T1 (de) Test für zelluläre immunität mittels an einen festen träger gebundener peptide